<DOC>
	<DOCNO>NCT02089581</DOCNO>
	<brief_summary>To determine whether two new oral formulation strong pain killer release drug body similar pattern already market reference capsule formulation without food .</brief_summary>
	<brief_title>A Study Whether 2 New Oral Formulations Strong Pain Killer Release Same Amount Drug Into Body Marketed Medication</brief_title>
	<detailed_description>Comparisons make two new oral formulation exist market reference capsule formulation determine whether release rate product similar equivalent fed fast state . Determination measurement drug concentration blood serial collection time point pre-dose 32 hour post-dose , follow administration single oral dose . Pharmacokinetics parameter AUC Cmax primary endpoint .</detailed_description>
	<mesh_term>Analgesics</mesh_term>
	<criteria>Inclusion Criteria Healthy male female subject age 18 55 inclusive . Female subject sexually active become sexually active must willing use highly effective method contraception throughout study . A highly effective method birth control define one result low failure rate ( i.e . le 1 % per year ) use consistently correctly sterilisation , implant , injectables , combine oral contraceptive , IUDs ( Intrauterine Device ) , vasectomise partner . Female subject less one year postmenopausal must negative serum pregnancy test nonlactating . Female subject postmenopausal &gt; 1 year elevate serum folliclestimulating hormone ( FSH ) treat hormone replacement therapy ( HRT ) . Male subject must willing use contraception partner throughout study 30 day completion study agree inform Investigator partner become pregnant time . Body weight range 55 100 kg BMI ≥ 18.5 ≤ 29.9 . Healthy free significant abnormal finding determine medical history , physical examination , vital sign , laboratory test ECG . Willing eat food supply throughout study . The subject 's primary care physician confirm within last 12 month nothing medical history would preclude enrolment clinical study . Exclusion Criteria Any history drug alcohol abuse . Any history condition might interfere drug absorption , distribution , metabolism excretion . Use opioid opioid antagonistcontaining medication past 30 day . Any history frequent nausea vomit regardless etiology . Any history seizures symptomatic head trauma . Paralytic ileus , respiratory depression , hypoxia elevate carbon dioxide level blood . Participation clinical drug study 90 day precede initial dose study . Subjects must participate pilot definitive phase one Cohort . Any significant illness 4 week precede entry study . Use medication include vitamin , herbal and/or mineral supplement 7 day precede initial dose course study ( exception continue use HRT contraceptive ) . Note : subject take oral contraceptive contain CYP3A4 inhibitor gestodene exclude may lead elevate plasma concentration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Healthy Volunteer</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Bioequivalence</keyword>
</DOC>